Japan Medical Dynamic Marketing, Inc. (7600) AI Stock Analysis

• Market Cap: ¥13.38B
• Dividend Yield: 3.12%
• Average Volume (3M): 89.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: 3.59%
• EPS Growth: -163.08%
• Country: JP
• Employees: 511
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.15
• Shares Outstanding: 26,475,880
• 10 Day Avg. Volume: 96,020
• 30 Day Avg. Volume: 89,743
• PEG Ratio: 0.24
• Price to Book (P/B): 0.61
• Price to Sales (P/S): 0.60
• P/FCF Ratio: -29.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ¥538.00 ▲(10.47% Upside)

The overall stock score of 58 reflects the company's stable revenue growth and strong balance sheet, offset by profitability challenges and negative free cash flow. Technical indicators suggest a neutral trend with potential risks of a pullback. Valuation is impacted by negative earnings, but the dividend yield offers some investor appeal.

Positive Factors

Stable Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business sustainability.

Strong Balance Sheet

A robust balance sheet with low leverage enhances financial stability, providing resilience against economic fluctuations.

Strategic Collaborations

Partnerships with healthcare institutions can drive revenue growth and market penetration, strengthening competitive positioning.

Negative Factors

Profitability Challenges

Sustained profitability issues can hinder reinvestment and growth, potentially impacting long-term business viability.

Negative Free Cash Flow

Negative free cash flow may constrain the company's ability to fund operations and growth, necessitating external financing.

Declining Margins

Eroding margins can reduce profitability and competitiveness, requiring cost management to maintain financial health.

Japan Medical Dynamic Marketing, Inc. Business Overview & Revenue Model

Company Description

Japan Medical Dynamic Marketing, INC. develops, manufactures, imports, and sells medical devices in Japan and the United States. The company provides trauma devices, including nails, screws, plates, and other products surgically implanted in the fracture site; joint prostheses, which replaces natural joints and restores functions damaged or lost due to disease or injury; spinal fixation devices for the use in spinal instability surgery; and artificial bone fillers for the treatment of bone fractures, tumors, and other defects. It offers its products to medical professionals and hospitals. The company was incorporated in 1973 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Japan Medical Dynamic Marketing, Inc. generates revenue through multiple streams, primarily from the sales of its medical devices and pharmaceuticals to hospitals and clinics. The company partners with various manufacturers to distribute their products, earning a margin on sales. Additionally, it may generate income through service contracts for maintenance and support of its medical equipment. Other revenue streams could include consulting services related to product implementation and training for healthcare professionals. Strategic collaborations with healthcare institutions and participation in government healthcare initiatives further bolster its earnings potential.

Japan Medical Dynamic Marketing, Inc. Financial Statement Overview

Summary

Japan Medical Dynamic Marketing, Inc. shows stable revenue growth but faces challenges with profitability as seen in the negative net income in 2025. The balance sheet remains robust with low leverage, but cash flow management is an area of concern due to negative free cash flow. Continued focus on cost management and improving cash flow will be crucial for future financial health.

Income Statement

The company experienced a moderate revenue growth rate over recent years, with a notable increase from 2024 to 2025. However, the net profit margin turned negative in 2025, indicating profitability challenges. Gross profit margins have remained relatively stable, but declining EBIT and EBITDA margins suggest rising operational costs.

Balance Sheet

The balance sheet shows a strong equity base with a healthy equity ratio, demonstrating financial stability. The debt-to-equity ratio is relatively low, indicating conservative leverage. However, a decrease in stockholders' equity in 2025 could be a concern if it continues.

Cash Flow

Free cash flow has fluctuated, turning negative in 2025, which might impact liquidity. The operating cash flow to net income ratio shows adequate cash conversion, but the negative free cash flow raises concerns about the company's ability to fund operations and growth without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	24.98B	25.11B	23.18B	21.31B	19.19B	16.74B
Gross Profit	14.46B	15.65B	14.76B	13.99B	12.99B	11.42B
EBITDA	1.03B	1.40B	3.27B	3.35B	4.21B	3.47B
Net Income	-669.47M	-461.80M	1.27B	1.42B	2.14B	1.66B
Balance Sheet
Total Assets	32.22B	33.67B	31.49B	29.43B	27.34B	25.19B
Cash, Cash Equivalents and Short-Term Investments	2.35B	3.18B	2.32B	2.80B	2.59B	2.47B
Total Debt	4.35B	3.29B	1.49B	1.87B	1.85B	3.09B
Total Liabilities	8.25B	8.93B	5.88B	6.14B	5.85B	6.48B
Stockholders Equity	23.96B	24.68B	25.51B	23.16B	21.39B	18.63B
Cash Flow
Free Cash Flow	0.00	-504.10M	302.45M	870.67M	1.53B	1.23B
Operating Cash Flow	0.00	1.05B	2.10B	2.19B	3.11B	2.60B
Investing Cash Flow	0.00	-1.67B	-1.80B	-1.48B	-1.75B	-1.35B
Financing Cash Flow	0.00	1.49B	-840.71M	-514.78M	-1.29B	-1.31B

Japan Medical Dynamic Marketing, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 487.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7600, the sentiment is Positive. The current price of 487 is below the 20-day moving average (MA) of 487.25, below the 50-day MA of 487.10, and below the 200-day MA of 526.34, indicating a neutral trend. The MACD of 4.91 indicates Negative momentum. The RSI at 69.86 is Neutral, neither overbought nor oversold. The STOCH value of 87.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7600.

Japan Medical Dynamic Marketing, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
5187	78 Outperform	¥9.43B	11.57	―	3.52%	4.97%	-10.07%
6678	78 Outperform	¥19.02B	15.69	―	3.02%	-4.36%	-14.92%
7963	74 Outperform	¥9.64B	12.47	―	1.89%	9.47%	37.35%
7792	71 Outperform	¥13.57B	10.19	―	2.90%	16.37%	29.02%
7600	58 Neutral	¥13.38B	-15.06	―	3.12%	3.59%	-163.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7777	48 Neutral	¥42.31B	-380.62	1.45%	―	40.50%	91.59%

Japan Medical Dynamic Marketing, Inc. Corporate Events

Japan Medical Dynamic Marketing Revises Earnings Forecast Amid Supply Chain Challenges

Japan Medical Dynamic Marketing, Inc. has revised its consolidated earnings forecast for the fiscal year ending March 2026, citing increased sales from its new ‘Trivicta Hip Stem’ in the U.S. However, supply chain issues with outsourced knee joint products and rising costs are expected to impact profits negatively. The company is implementing strategies to improve efficiency and profitability, including a cost reduction project and direct shipping to Japan. Despite the forecast revision, the company maintains its annual dividend policy, emphasizing its commitment to shareholder returns.

The most recent analyst rating on (JP:7600) stock is a Hold with a Yen538.00 price target. To see the full list of analyst forecasts on Japan Medical Dynamic Marketing, Inc. stock, see the JP:7600 Stock Forecast page.

Japan Medical Dynamic Marketing Reports Decline in Semi-Annual Financial Performance

Japan Medical Dynamic Marketing, Inc. reported a decline in its financial performance for the six months ending September 30, 2025, with net sales decreasing by 1.8% and operating profit dropping by 68.9% compared to the previous year. The company has revised its financial forecasts for the fiscal year ending March 31, 2026, indicating a challenging market environment and potential impacts on stakeholders.

The most recent analyst rating on (JP:7600) stock is a Hold with a Yen538.00 price target. To see the full list of analyst forecasts on Japan Medical Dynamic Marketing, Inc. stock, see the JP:7600 Stock Forecast page.